Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.
